Endogenous glycosides in critically ill patients

Critical Care Medicine
Elmar BerendesMichael Walter

Abstract

To determine the incidence of critically ill patients displaying endogenous digitalis-like-immunoreactive substances (DLIS) and to examine the relationship of these hormones to routine laboratory variables, the underlying disease, myocardial function, hemodynamic status, severity of illness, systemic inflammation, and mortality rate. Sera of 401 consecutive critically ill patients, not treated with cardiac glycosides, were analyzed for DLIS (digitoxin and digoxin, TDx; Abbott Diagnostics, North Chicago, IL) and endogenous ouabain. Normal values of endogenous ouabain were determined in 62 healthy volunteers. We measured pro- and anti-inflammatory mediators (L-selectin, tumor necrosis factor-alpha, interleukin-1beta, interleukin-2, interleukin-6, interleukin-10), C-reactive protein, and serum amyloid A protein as well as patients' Acute Physiology and Chronic Health Evaluation II and Goris scores. In a subgroup of patients with a pulmonary artery catheter (n = 95), we determined cardiac output, pulmonary artery occlusion pressure, systemic and pulmonary vascular resistance, left ventricular stroke volume, and right and left stroke work. Two surgical intensive care units of an university hospital. Sera of 401 consecutive criticall...Continue Reading

References

Jun 1, 1991·Hypertension·D W HarrisD W DuCharme
Jul 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·J M HamlynJ H Ludens
Jan 1, 1991·Gynecologic and Obstetric Investigation·P JakobiG Ziskind
Jan 1, 1989·Journal of Pharmaceutical and Biomedical Analysis·P MojaverianG D Chase
Jan 1, 1988·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·S S YangR Williams
Mar 1, 1989·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·S S YangA J Keyser
Oct 1, 1985·Archives of Surgery·R J GorisJ S Gimbrère
Nov 16, 1972·The New England Journal of Medicine·M C RogersT W Smith
Oct 1, 1984·Annals of Internal Medicine·M H GaultL L Longerich
Nov 1, 1983·Annals of Internal Medicine·S W GravesR Valdes
Sep 1, 1994·The Clinical Investigator·M P Blaustein
Jun 1, 1994·Anesthesiology·E BerendesP Lawin
Jan 1, 1994·Journal of Internal Medicine·A Y BagrovO V Fedorova
Feb 1, 1996·Journal of Hypertension·J M HamlynP Manunta
Jul 31, 1998·Clinical and Experimental Hypertension : CHE·J M HamlynB P Hamilton
Jul 31, 1998·Clinical and Experimental Hypertension : CHE·J W Van Huysse, F H Leenen
Jul 31, 1998·Clinical and Experimental Hypertension : CHE·M P BlausteinV A Golovina

❮ Previous
Next ❯

Citations

Jan 15, 2013·Critical Care Medicine·Elena BignamiPaolo Manunta
Jul 6, 2007·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Wilhelm Schoner, Georgios Scheiner-Bobis
Aug 13, 2013·BioMed Research International·Mehmet YalazNilgun Kultursay
Feb 11, 2014·Clinica Chimica Acta; International Journal of Clinical Chemistry·Silvia BaecherMichael Vogeser
Jun 13, 2014·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Marco SimoniniUNKNOWN CABG Genomics Investigators
Mar 19, 2011·Pathophysiology : the Official Journal of the International Society for Pathophysiology·Michael Eisenhut, Juhani Leppäluoto
Jan 10, 2006·Critical Care Clinics·Eric S NylénRahul Khosla
Mar 26, 2004·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Uday M Khosla, Richard J Johnson
Mar 9, 2010·Biochemical and Biophysical Research Communications·Peter KolkhofJan Torzewski
Nov 28, 2017·Frontiers in Physiology·Luiz H A Cavalcante-SilvaSandra Rodrigues-Mascarenhas
Aug 31, 2018·International Journal of Molecular Sciences·David J KennedyW H Wilson Tang
Dec 4, 2008·Journal of Hypertension·Paolo ManuntaJohn M Hamlyn
May 15, 2007·American Journal of Physiology. Cell Physiology·Wilhelm Schoner, Georgios Scheiner-Bobis
Dec 5, 2012·Current Opinion in Nephrology and Hypertension·John M Hamlyn, Mordecai P Blaustein
Jun 12, 2019·Oxidative Medicine and Cellular Longevity·Chao ShaoJinjun Bian
Oct 27, 2020·Frontiers in Physiology·Sergej PirkmajerAlexander V Chibalin
Jan 22, 2020·Genes & Diseases·Sergei N OrlovElizaveta A Klimanova

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Cardiac Glycosides

Cardiac glycosides are a diverse family of naturally derived compounds that bind to and inhibit na+/k+-atpase. Discover the latest research on cardiac glycosides heres.